Allscripts (MDRX) Misses Q4 EPS by 1c, Offers Guidnce
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Oracle shares drop on AI spending concerns and Microsoft criticism
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Jefferies Reiterates Buy on Allscripts (MDRX) Following 4Q
February 17, 2017 8:26 AM ESTJefferies reiterated a Buy rating and $16.50 price target on Allscripts (NASDAQ: MDRX) following 4Q earnings report. MDRX reported EPS of $0.14, which compares to $0.15 for consensus. Downside was driven by higher SG&A, partially offset by better revenue, a higher gross margin and... More
Allscripts (MDRX) PT Raised to $13 at Cantor Fitzgerald Following In-Line 4Q Results
February 17, 2017 7:22 AM ESTCantor Fitzgerald analyst Steven Halper reiterates Neutral rating and raises price target on Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) to $13 (from $12), suggesting shares remain fairly valued, as the company reported 2016 fourth quarter results in-line with estimates, while 2017 guidance was also in-line with... More



